- 2025.
- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
- 2025.
- 2024.
- 2023.
- 2022.
- 2021.
- 2020.
- 2019.
- 2018.
- 2017.
- 2016.
- 2015.
- 2014.
- 2013.
- 2012.
- 2011.
- 2010.
- 2009.
- 2008.
- 2007.
- 2006.
- 2005.
- 2004.
- 2003.
- 2002.
- 2001.
- 2000.
- 1999.
- 1998.
2024.
-
- Dec.03.2024 Licensing
- Ono Enters into Drug Discovery Collaboration Agreement with Congruence Therapeutics to Generate Novel Small Molecule Correctors in the Oncology Area
-
- Oct.10.2024 Licensing
- Ono Enters into License Agreement for LCB97, an Antibody-Drug Conjugate, and Research Collaboration and License Agreement to generate novel ADC candidates by leveraging ConjuAll™ ADC platform with LigaChem Biosciences
-
- Aug.01.2024 Licensing
- Ono Enters into a New Option and Research Collaboration Agreement with Monash University to Discover and Create New Anti-GPCR Antibodies in the Autoimmune and Inflammatory Diseases
-
- Apr.25.2024 Licensing
- Ono Enters into a Collaboration Agreement with PRISM BioLab to Generate Novel Drug Candidates in the Oncology Area
-
- Mar.22.2024 Licensing
- Ono Enters into Comprehensive Drug Discovery Collaboration Agreement with University of Oxford
-
- Mar.14.2024 Licensing
- Ono Enters into a Collaboration Agreement with Sibylla Biotech to Generate Novel Drug Candidates for Neurological Disorders
-
- Mar.11.2024 Licensing
- ONO Enters into a University-Wide, Research Alliance Agreement with Harvard University
-
- Mar.06.2024 Licensing
- Ono Enters into a License Agreement with NEX-I to Develop and Commercialize NXI-101
-
- Feb.21.2024 Licensing
- Ono Enters into a Drug Discovery Collaboration Agreement with EME Aiming at the Generation of Novel VHH Antibody Drugs
-
- Feb.19.2024 Licensing
- Ono Enters into a Research Collaboration Agreement with InveniAI to Identify Novel Therapeutic Targets
-
- Feb.14.2024 Licensing
- ONO Enters into an Option and Collaboration Agreement with Numab to Develop Multi-specific Antibody NM49
-
- Feb.13.2024 Licensing
- Ono Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins
2023.
-
- Dec.20.2023 Licensing
- Ono Enters into Research Collaboration with UK Dementia Research Institute
-
- Dec.19.2023 Licensing
- Ono Enters into Collaboration Agreement with EVQLV to Generate Novel Antibodies against Multiple Targets Utilizing EVQLV’s AI-powered Antibody Design Engine for Development of Innovative Antibody Drugs
-
- Oct.24.2023 Licensing
- Ono Enters into a Research Collaboration Agreement with Turbine to Identify and Validate Novel Therapeutic Targets in Oncology
-
- Sep.27.2023 Licensing
- Ono Enters into a Drug Discovery Collaboration Agreement with Adimab to Discover Novel Antibody Drugs in the Oncology Field
-
- Aug.31.2023 Licensing
- Ono Enters into a Drug Discovery Collaboration Agreement with Twist Bioscience to Discover Novel Antibodies for Autoimmune Diseases
-
- Mar.23.2023 Licensing
- Ono Enters into a Drug Discovery Collaboration Agreement with Macomics to Develop Macrophage-targeting Antibody Therapy for the Treatment of Cancer
-
- Mar.23.2023 Licensing
- Ono Enters into a Drug Discovery Collaboration Agreement with MOLCURE to Discover and Develop Innovative Antibody Drugs for Multiple Targets Utilizing MOLCURE’s AI-driven Platform Technology
-
- Mar.15.2023 Licensing
- Ono Enters into a Drug Discovery Collaboration Agreement with PeptiDream to Discover and Develop Macrocyclic Constrained Peptide Therapeutics
-
- Feb.22.2023 Licensing
- Ono Enters into a Collaboration and Option Agreement with Cue Biopharma for CUE-401, a Bispecific Protein
-
- Jan.25.2023 Licensing
- Ono Acquires Multiple Research-Stage Oncology Programs from KSQ Therapeutics
-
- Jan.13.2023 Licensing
- Ono Enters an Option and Research Collaboration Agreement with Monash University to Discover Anti-GPCR Antibodies in the Autoimmune and Inflammatory Diseases
2022.
-
- Dec.14.2022 Licensing
- Ono Enters into a Multi Target R&D Collaboration Agreement with PrecisionLife
-
- Dec.06.2022 Licensing
- Ono and Equillium Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of Itolizumab
-
- Nov.14.2022 Licensing
- Ono Enters a Drug Discovery Collaboration Agreement with Captor Therapeutics to Develop Small Molecule Protein Degraders for the Treatment of Neurodegenerative Diseases
-
- Nov.07.2022 Licensing
- Ono Exercises Option to HER2-targeted CAR T-Cell Product Candidate for Solid Tumors Generated from the Collaboration with Fate Therapeutics
-
- Nov.01.2022 Licensing
- Ono Enters a Drug Discovery Collaboration Agreement with Memo Therapeutics to Discover and Develop Antibody Drugs in the Immuno-oncology Field
-
- Jun.28.2022 Licensing
- ONO Announces Expanded Collaboration with Fate Therapeutics on iPSC-derived CAR-T Cell and CAR-NK Cell Therapies for Solid Tumors
-
- Apr.19.2022 Licensing
- Ono Enters into Collaboration Agreement with Domain Therapeutics and Université de Montréal for GPCR-Targeted Drug Discovery
-
- Mar.31.2022 Licensing
- ONO Enters into a Development and License Agreement with Numab
-
- Mar.30.2022 Licensing
- ONO Enters into Collaboration Agreement with Iktos
-
- Jan.17.2022 Licensing
- Ono Expands Drug Discovery Collaboration with Neurimmune AG in the Field of Neurodegenerative Diseases
2021.
-
- Dec.22.2021 Licensing
- Ono Extends Drug Discovery Collaboration Agreement with Vanderbilt University
-
- Aug.10.2021 Licensing
- Ono Enters into Drug Discovery Collaboration Agreement with MiraBiologics To Discover and Create Biopharmaceuticals
-
- Aug.04.2021 Licensing
- Ono Enters into Research Collaboration Agreement with Healx Limited
-
- Mar.01.2021 Licensing
- ONO Entered License Agreement with PeptiDream Inc. on Automated Peptide Discovery Platform System (PDPS) Platform
-
- Feb.02.2021 Licensing
- ONO enters into License Agreement with Ribon Therapeutics for the Development and Commercialization of RBN-2397, a PARP7 Inhibitor, in Japan, South Korea, Taiwan and ASEAN Countries
2020.
-
- Dec.15.2020 Licensing
- ONO Enters into Exclusive License Agreement with Chordia Therapeutics on CTX-177, a MALT1 Inhibitor, and its Related Compounds(131 KB)
-
- Nov.09.2020 Licensing
- ONO and Bristol Myers Squibb Enter Patent License Agreement with Roche(129 KB)
-
- Oct.13.2020 Licensing
- Ono Enters into License Agreement on Cenobamate, an Antiepileptic Drug with SK Biopharmaceuticals(156 KB)
-
- Mar.30.2020 Licensing
- ONO Enters into a New Research and Option Agreement with Numab(123 KB)
-
- Mar.05.2020 Licensing
- ONO and Nichi-Iko Enter into Licensing Agreement and Technical Collaboration for Limaprost Alfadex Tablets(94 KB)
2019.
-
- Jul.19.2019 Licensing
- Bayer, Bristol-Myers Squibb and Ono Pharmaceutical enter into a clinical collaboration agreement to investigate Stivarga® (regorafenib) and Opdivo® (nivolumab) as combination therapy in patients with colorectal cancer(62 KB)
-
- Jul.11.2019 Licensing
- ONO and Forty Seven, Inc. Sign a License Agreement to Develop, Manufacture and Commercialize 5F9 in Japan, South Korea, Taiwan and Other Selected Countries in Southeast Asia(64 KB)
-
- Jun.25.2019 Licensing
- ONO Enters into Exclusive License Agreement with Rafael Pharmaceuticals on CPI-613 (devimistat), a Cancer Metabolism Inhibitor, and Other Related Compounds(40 KB)
-
- Mar.27.2019 Licensing
- ONO Announces a Strategic Drug Discovery Alliance Agreement with Cancer Research UK and LifeArc for Cancer Immunotherapy(63 KB)
-
- Mar.18.2019 Licensing
- Ono Enters into Research Collaboration Agreement with twoXAR, Inc.(37 KB)
-
- Jan.31.2019 Licensing
- ONO Announces a Strategic Partnership Agreement with Repare Therapeutics for a Pol-theta Inhibitor Program(105 KB)
2018.
-
- Sep.18.2018 Licensing
- ONO announces collaboration with Fate Therapeutics for two iPSC-derived CAR-T Therapies for Cancers(66 KB)
-
- Aug.28.2018 Licensing
- Ono Enters into Collaboration Agreement on Combination Therapy of Opdivo® and Rubraca® with BMS and Clovis(68 KB)
-
- Aug.22.2018 Licensing
- Ono and Takeda Initiate Clinical Collaboration on Combination Therapy of Opdivo® (Nivolumab) and Cabozantinib in Japan(74 KB)
-
- Mar.14.2018 Licensing
- Ono Enters into New Collaboration Agreement with Merus N.V.(104 KB)
2017.
-
- Dec.19.2017 Licensing
- ONO enters into Collaboration Agreement with Schrödinger Inc.(40 KB)
-
- Dec.14.2017 Licensing
- ONO Enters into License Agreement with Bristol-Myers Squibb for Prostaglandin E2 Receptor Antagonists relating to Immuno-Oncology Programs(43 KB)
-
- Dec.12.2017 Licensing
- Ono Enters into Collaboration Agreement with Cyclenium Pharma, Inc.(33 KB)
-
- Nov.09.2017 Licensing
- ONO announces collaboration with Neurimmune in Neurodegenerative Diseases Field(58 KB)
-
- Oct.12.2017 Licensing
- Ono Enters into Exclusive License Agreement with Karyopharm to Develop and Commercialize Selinexor and KPT-8602, XPO1 Inhibitors(76 KB)
-
- Sep.08.2017 Licensing
- CONCLUSION OF DEVELOPMENT COLLABORATION AGREEMENT FOR OPDIVO® (NIVOLUMAB) AND LENVIMA® (LENVATINIB MESYLATE) COMBINATION THERAPY FOR TREATMENT OF HEPATOCELLULAR CARCINOMA(121 KB)
-
- Sep.01.2017 Licensing
- Ono and Seikagaku Reach a Definitive Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan(47 KB)
-
- May.31.2017 Licensing
- ONO Concludes a License Agreement with Array Biopharma related to Binimetinib, a MEK inhibitor and Encorafenib, a BRAF inhibitor(58 KB)
-
- May.12.2017 Licensing
- Seikagaku and Ono Reach a Basic Agreement Related to Co-development and Marketing Collaboration on SI-613 for the Treatment of Osteoarthritis in Japan(46 KB)
-
- Mar.28.2017 Licensing
- ONO Enters into a Research and Option Agreement with Numab(41 KB)
-
- Mar.21.2017 Licensing
- Ono Enters into Collaboration Agreement with X-Chem, Inc.(52 KB)
-
- Jan.21.2017 Licensing
- Ono Pharmaceutical Company and Bristol-Myers Squibb Enter Settlement and License Agreement with Merck for Anti-PD-1 Antibody Patent Infringement Litigation(79 KB)